PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2024; 124(07): 684-694
DOI: 10.1055/s-0043-1771188
Original Article: Atherosclerosis and Ischaemic Disease

Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in Asia

Peizhi Wang   *
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Deshan Yuan   *
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Xueyan Zhao
2   Special Demand Medical Care Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Pei Zhu
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Xiaogang Guo
3   Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
,
Lin Jiang
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Na Xu
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Zhifang Wang
4   Department of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan Province, China
,
Ru Liu
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Qingsheng Wang
5   Department of Cardiology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei Province, China
,
Yan Chen
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Yongzhen Zhang
6   Department of Cardiology, Peking University Third Hospital, Beijing, China
,
Jingjing Xu
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Zhenyu Liu 
7   Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Ying Song
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Zheng Zhang
8   Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China
,
Yi Yao
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Yingqing Feng
9   Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangzhou, Guangdong Province, China
,
Xiaofang Tang
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Xiaozeng Wang
10   Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning Province, China
,
Runlin Gao
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Yaling Han   **
10   Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning Province, China
,
Jinqing Yuan   **
1   Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11   National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
› Institutsangaben
Funding This work was supported by grants from the Ministry of Science and Technology of the People's Republic of China [2016YFC1301300 and 2016YFC1301301], National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences [Grant No. NCRC2020013], and the CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-C&T-B-049]. The funding organizations had no role in the study's design and concept; the collection, management, analysis, and interpretation of the data; or the manuscript's preparation, review, or approval. National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Grant No. NCRC2020013. The CAMS Innovation Fund for Medical Sciences (CIFMS), 2020-I2M-C&T-B-049. The Ministry of Science and Technology of the People's Republic of China, 2016YFC1301300 and 2016YFC1301301. Fundamental Research Funds for the Central Universities, Grant No. 3332023128.
› Weitere Informationen
  Lizenzen und Reprints


Abstract

Background Lipoprotein(a), or Lp(a), has been recognized as a strong risk factor for atherosclerotic cardiovascular disease. However, the relationship between Lp(a) and bleeding remains indistinct, especially in the secondary prevention population of coronary artery disease (CAD). This investigation aimed to evaluate the association of Lp(a) with long-term bleeding among patients with CAD.

Methods Based on a prospective multicenter cohort of patients with CAD consecutively enrolled from January 2015 to May 2019 in China, the current analysis included 16,150 participants. Thus, according to Lp(a) quintiles, all subjects were divided into five groups. The primary endpoint was bleeding at 2-year follow-up, and the secondary endpoint was major bleeding at 2-year follow-up.

Results A total of 2,747 (17.0%) bleeding and 525 (3.3%) major bleeding were recorded during a median follow-up of 2.0 years. Kaplan–Meier survival analysis showed the highest bleeding incidence in Lp(a) quintile 1, compared with patients in Lp(a) quintiles 2 to 5 (p < 0.001), while the incidence of major bleeding seemed similar between the two groups. Moreover, restricted cubic spline analysis suggested that there was an L-shaped association between Lp(a) and 2-year bleeding after adjustment for potential confounding factors, whereas there was no significant association between Lp(a) and 2-year major bleeding.

Conclusion There was an inverse and L-shaped association of Lp(a) with bleeding at 2-year follow-up in patients with CAD. More attention and effort should be made to increase the clinician awareness of Lp(a)'s role, as a novel marker for bleeding risk to better guide shared-decision making in clinical practice.

Keywords

lipoprotein(a) - bleeding - inverse association - L-shaped association - prognosis

Authors' Contribution

P.W., D.Y., J.Y., and Y.H. contributed to the study design. P.Z., L.J., N.X., R.L., Y.C., J.X., Y.S., Y.Y., and X.T. participated in the collection, analysis, or interpretation of data. P.W. and D.Y. performed the statistical analysis and drafted the manuscript. J.Y., Y.H., R.G., X.W., Y.F., Z.Z., Z.L., Y.Z., Q.W., Z.W., X.G., and X.Z. critically revised the manuscript. All authors read and approved the final submitted version.


* These authors shared first co-authorship.


** These authors Han shared last co-authorship.


Supplementary Material



Publikationsverlauf

Eingereicht: 07. Dezember 2022

Angenommen: 08. Juni 2023

Artikel online veröffentlicht:
24. Juli 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: a review. JAMA Cardiol 2022; 7 (07) 760-769
    CrossrefPubMedSuche in Google Scholar
  • 2 Di Fusco SA, Arca M, Scicchitano P. et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart 2022; 109 (01) 18-25
    CrossrefPubMedSuche in Google Scholar
  • 3 Erqou S, Kaptoge S, Perry PL. et al; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302 (04) 412-423
    CrossrefPubMedSuche in Google Scholar
  • 4 Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 61 (11) 1146-1156
    CrossrefPubMedSuche in Google Scholar
  • 5 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 (24) 3168-3209
    CrossrefPubMedSuche in Google Scholar
  • 6 Cao YX, Zhang HW, Jin JL. et al. Lipoprotein(a) and cardiovascular outcomes in patients with previous myocardial infarction: a prospective cohort study. Thromb Haemost 2021; 121 (09) 1161-1168
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 von Zychlinski A, Kleffmann T, Williams MJ, McCormick SP. Proteomics of lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteomics 2011; 74 (12) 2881-2891
    CrossrefPubMedSuche in Google Scholar
  • 8 Ishikawa S, Kotani K, Kario K. et al; Jichi Medical School (JMS) cohort study group. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb Res 2013; 131 (02) e54-e58
    CrossrefPubMedSuche in Google Scholar
  • 9 Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a Mendelian randomization study. Clin Chem 2017; 63 (11) 1714-1723
    CrossrefPubMedSuche in Google Scholar
  • 10 Chen Y, Zhan X, Zhao Q. et al. Serum lipoprotein(a) and risk of hemorrhagic stroke among incident peritoneal dialysis patients: a large study from a single center in China. Ren Fail 2019; 41 (01) 800-807
    CrossrefPubMedSuche in Google Scholar
  • 11 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68 (10) 1082-1115
    CrossrefPubMedSuche in Google Scholar
  • 12 Valgimigli M, Cao D, Angiolillo DJ. et al; XIENCE 90 and XIENCE 28 Investigators. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI. J Am Coll Cardiol 2021; 78 (21) 2060-2072
    CrossrefPubMedSuche in Google Scholar
  • 13 Leong DP, Joseph PG, McKee M. et al. Reducing the global burden of cardiovascular disease, Part 2: prevention and treatment of cardiovascular disease. Circ Res 2017; 121 (06) 695-710
    CrossrefPubMedSuche in Google Scholar
  • 14 Kaasenbrood L, Boekholdt SM, van der Graaf Y. et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016; 134 (19) 1419-1429
    CrossrefPubMedSuche in Google Scholar
  • 15 Nakamura M, Kadota K, Nakao K. et al. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry. EuroIntervention 2021; 16 (14) 1154-1162
    CrossrefPubMedSuche in Google Scholar
  • 16 O'Donoghue ML, Rosenson RS, Gencer B. et al; OCEAN(a)-DOSE Trial Investigators. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 387 (20) 1855-1864
    CrossrefPubMedSuche in Google Scholar
  • 17 Yeang C, Karwatowska-Prokopczuk E, Su F. et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol 2022; 79 (11) 1035-1046
    CrossrefPubMedSuche in Google Scholar
  • 18 Cosentino F, Grant PJ, Aboyans V. et al; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41 (02) 255-323
    CrossrefPubMedSuche in Google Scholar
  • 19 Williams B, Mancia G, Spiering W. et al; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33) 3021-3104
    CrossrefPubMedSuche in Google Scholar
  • 20 Neumann FJ, Sousa-Uva M, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
    CrossrefPubMedSuche in Google Scholar
  • 21 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedSuche in Google Scholar
  • 22 Roth GA, Mensah GA, Johnson CO. et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020; 76 (25) 2982-3021
    CrossrefPubMedSuche in Google Scholar
  • 23 Yuan D, Wang P, Jia S. et al. Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. Atherosclerosis 2022; 363: 109-116
    CrossrefPubMedSuche in Google Scholar
  • 24 Clarke R, Peden JF, Hopewell JC. et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361 (26) 2518-2528
    CrossrefPubMedSuche in Google Scholar
  • 25 Mach F, Baigent C, Catapano AL. et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188
    CrossrefPubMedSuche in Google Scholar
  • 26 Trinder M, Paruchuri K, Haidermota S. et al. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk. J Am Coll Cardiol 2022; 79 (07) 617-628
    CrossrefPubMedSuche in Google Scholar
  • 27 Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed) 2018; 23 (06) 1099-1112
    PubMedSuche in Google Scholar
  • 28 Law RH, Caradoc-Davies T, Cowieson N. et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012; 1 (03) 185-190
    CrossrefPubMedSuche in Google Scholar
  • 29 Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005; 10: 1754-1762
    PubMedSuche in Google Scholar
  • 30 Martínez C, Rivera J, Loyau S. et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost 2001; 85 (04) 686-693
    Thieme ConnectPubMedSuche in Google Scholar
  • 31 Anglés-Cano E, de la Peña Díaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001; 936: 261-275
    CrossrefPubMedSuche in Google Scholar
  • 32 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339 (6222): 301-303
    CrossrefPubMedSuche in Google Scholar
  • 33 Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res 2014; 55 (04) 625-634
    CrossrefPubMedSuche in Google Scholar
  • 34 Riches K, Porter KE. Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol 2012; 2012: 923289
    CrossrefPubMedSuche in Google Scholar
  • 35 Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system?. Thromb Haemost 1990; 63 (03) 331-335
    Thieme ConnectPubMedSuche in Google Scholar
  • 36 Mehta A, Jain V, Saeed A. et al. Lipoprotein(a) and ethnicities. Atherosclerosis 2022; 349: 42-52
    CrossrefPubMedSuche in Google Scholar